UCB announced findings from new studies of the once-daily antiepileptic drug (AED) Keppra XR(TM) (levetiracetam) extended-release tablets comparing tolerability versus levetiracetam immediate release (IR) and reporting on additional dosing schedules. The data were among five studies that were presented at the 62nd annual meeting of the American Epilepsy Society (AES) in Seattle.

In this new meta-analysis, patients taking Keppra XR experienced fewer nervous system side effects than those taking the same dose of twice daily levetiracetam. Keppra XR is the only once-daily, extended-release formulation of levetiracetam, and there is no generic alternative available.

For more information, click on the following link: http://www.medicalnewstoday.com/articles/132394.php